Literature DB >> 8103750

Suppression of apoptosis in normal and neoplastic human B lymphocytes by CD40 ligand is independent of Bc1-2 induction.

M J Holder1, H Wang, A E Milner, M Casamayor, R Armitage, M K Spriggs, W C Fanslow, I C MacLennan, C D Gregory, J Gordon.   

Abstract

The tendency of isolated germinal center (GC) B cells to undergo apoptosis was suppressed by recombinant cell-bound CD40 ligand (CD40L): after 2 days at 37 degrees C, > 80% of cells remained viable in the presence of CD40L as compared to < 1% in control cultures. CD40L sustained a high rate of DNA synthesis in GC cells and was more effective than monoclonal antibody to CD40 in this regard. Group I Burkitt lymphoma (BL) cell lines induced to undergo apoptosis with anti-immunoglobulin or calcium ionophore were also protected by CD40L. In BL cells, this route of rescue was not accompanied by induction of Bc1-2 protein, the expression of which has been linked to hemopoietic cell survival. Bc1-2 was induced in GC cells responding to CD40L, but its appearance was a relatively late event not reaching significant levels over controls until day 2 of culture. Thus induction of Bc1-2 appears to be secondary to the survival signal imparted by CD40L. These findings are discussed in relation to a potential role for CD40L in supporting B cell tumors in vivo and the discovery that the molecular defect in the X-linked Hyper-IgM syndrome is targeted to the CD40L gene.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8103750     DOI: 10.1002/eji.1830230948

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  20 in total

Review 1.  Fortifying B cells with CD154: an engaging tale of many hues.

Authors:  J Gordon; J D Pound
Journal:  Immunology       Date:  2000-07       Impact factor: 7.397

Review 2.  Life and death within germinal centres: a double-edged sword.

Authors:  Liliana Guzman-Rojas; Jennifer C Sims-Mourtada; Roberto Rangel; Hector Martinez-Valdez
Journal:  Immunology       Date:  2002-10       Impact factor: 7.397

3.  Inhibition of B-cell death does not restore T-cell-dependent immune responses in CD40-deficient mice.

Authors:  Jesús Merino; Miguel A Díez; María Muñiz; Luis Buelta; Gabriel Núñez; Marcos López-Hoyos; Ramón Merino
Journal:  Immunology       Date:  2003-08       Impact factor: 7.397

Review 4.  Molecular mechanism and function of CD40/CD40L engagement in the immune system.

Authors:  Raul Elgueta; Micah J Benson; Victor C de Vries; Anna Wasiuk; Yanxia Guo; Randolph J Noelle
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

Review 5.  The hyper-IgM (HIM) syndrome.

Authors:  N Ramesh; M Seki; L D Notarangelo; R S Geha
Journal:  Springer Semin Immunopathol       Date:  1998

6.  Pathogenic autoantibodies are routinely generated during the response to foreign antigen: a paradigm for autoimmune disease.

Authors:  S K Ray; C Putterman; B Diamond
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-05       Impact factor: 11.205

7.  Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma. Evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells.

Authors:  A Agathanggelou; G Niedobitek; R Chen; J Nicholls; W Yin; L S Young
Journal:  Am J Pathol       Date:  1995-10       Impact factor: 4.307

8.  CD40 expression by human peripheral blood eosinophils.

Authors:  Y Ohkawara; K G Lim; Z Xing; M Glibetic; K Nakano; J Dolovich; K Croitoru; P F Weller; M Jordana
Journal:  J Clin Invest       Date:  1996-04-01       Impact factor: 14.808

9.  Rescue of ileal Peyer's patch B cells from apoptosis is associated with the induction of Bcl-2 expression.

Authors:  B Motyka; J D Reynolds
Journal:  Immunology       Date:  1995-03       Impact factor: 7.397

10.  B cells from a distinct subset of patients with common variable immunodeficiency (CVID) have increased CD95 (Apo-1/fas), diminished CD38 expression, and undergo enhanced apoptosis.

Authors:  A Saxon; B Keld; D Diaz-Sanchez; B C Guo; N Sidell
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.